8/106 sources · 6 publishersUpdated Nov 4, 18:17 UTC
Medline raises full‑year organic sales outlook, launches $1 billion share buyback
Medline Inc. reported third‑quarter 2026 net sales of about $7.9 billion, up 10.4% year over year, while net income slipped 1.2% to $318 million. The board approved a share repurchase program authorizing up to $1 billion of stock buybacks. The company also lifted its full‑year 2026 organic sales growth guidance to a range of 10.0%‑10.5% and kept its adjusted EBITDA target of $3.3‑$3.4 billion unchanged.
Why it matters
The higher sales outlook suggests continued top‑line momentum, which may support the stock price. The new buyback program provides a direct return of capital to shareholders, potentially boosting earnings per share.
Key facts
- 1Third‑quarter 2026 net sales were $7.9 billion, an increase of 10.4% YoY. stocktitan.net
- 2Third‑quarter 2026 net income was $318 million, a decline of 1.2% YoY. stocktitan.net
- 3The board authorized a share repurchase program of up to $1 billion. stocktitan.net
- 4Full‑year 2026 organic sales growth guidance was raised to 10.0%‑10.5%. stocktitan.net
- 5Adjusted EBITDA guidance for FY 2026 remains $3.3‑$3.4 billion. stocktitan.net
- 6Adjusted EBITDA for Q3 2026 increased 11.8% to $960 million. tradingview.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.